News | Judith Tam ALK Lung Cancer Research Initiative

April 09, 2026: Welcome Dr. Collin Blakely, MD, PhD

Please join us in welcoming Dr. Collin Blakely, MD, PhD, as one of the newest members of our Scientific Advisory Board!

Dr. Blakely is a medical oncologist specializing in the treatment of lung cancer. He received his Bachelor of Science degree in Molecular and Cellular Biology from the University of Washington and attended the Perelman School of Medicine at the University of Pennsylvania in the Medical Scientist Training Program. He completed his Internal Medicine residency at the Hospital of the University of Pennsylvania and trained as a clinical fellow in Medical Oncology at UCSF.

His research focuses on understanding the cellular and molecular mechanisms underlying lung cancer resistance to EGFR- and ALK-targeted therapies and identifying new targets for molecular-directed therapies. His goal is to translate laboratory-based findings into new treatments for lung cancer patients.

April 07, 2026: Welcome Dr. Misako Nagasaka, MD, PhD

We are pleased to welcome Dr. Misako Nagasaka, MD, PhD, as one of the newest members of our Scientific Advisory Board!

Dr. Nagasaka is an Associate Clinical Professor of Thoracic Oncology in the Division of Hematology/Oncology, Department of Medicine at the University of California, Irvine. She completed her Internal Medicine residency at Beth Israel Medical Center and her Hematology/Oncology fellowship at Karmanos Cancer Institute.

Her clinical and research interests include molecular targeted therapy and immunotherapy for thoracic malignancies, with a particular focus on medical ethics. Dr. Nagasaka has authored 160+ publications, including work in The New England Journal of Medicine, Nature Medicine, Journal of Clinical Oncology, and Journal of Thoracic Oncology. She has served as site principal investigator for 20+ interventional clinical trials and as a sub-investigator on additional studies, and she actively collaborates with researchers nationally and internationally.

My fellows know that I always like to ask about what my patients enjoy doing, as I like to come up with a personalized plan. I’m excited to chat with you all during our upcoming discussions.

Dr. Misako Nagasaka, MD, PhD

October 26, 2025: Dr. Angel Qin MD., rejoined ALK Positive’s video series, ALKtALK, for an in-depth discussion with host Mark Rosenzweig about two Gilteritinib clinical trials and their significance for the ALK+ community.

March 07, 2025: Project 1 – Team training on a new instrument to enrich for live cells- allowing us to improve the quality of patient-derived material and study cells that survive therapy.

November 20, 2024: Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer

July 11, 2024: The Science and Research Communications team at ASCO announced they will highlight Dr. Sofia Merajver's 2024 ASCO Breakthrough abstract 215, “Precision medicine-based platform to guide the treatment of EML4-ALK driven lung cancers and other NSCLC in real time” at the ASCO Breakthrough Conference in Yokohama (August 10 - 24, 2024).

ALK Summit 2025

• July 18-20, 2025:  Drs. Sofia Merajver and Angel Qin attended the 2025 ALK+ Summit.
• July 18-20, 2025:  Members of the ALK Initiative team—including LiWei Bao, Sraboni Chaudhury, Ali Dabaja, Hassan Zbib, Mary Horn, Avery Rudnick, and Dr. Sofia Merajver—travel to the ALK Positive Summit in San Diego, CA, to lead and advance groundbreaking on-site blood collection for research.

Unlock the Summit: Watch All Expert Talks and Insights from the ALK Positive Summit.

ALK Summit 2024

• July 20, 2024: Dr. Angel Qin participates in the Key Opinion Leader (KOL) Panel w/ Case-based segments and Asks the Experts Breakout Session at the ALK Positive Summit in Nashville, TN. ALK Summit 2024 — ALK POSITIVE
• July 19-20, 2024: ALK Initiative team members Stacy Fry, Mary Horn, Habib Serhan, LiWei Bao, and Dr. Sofia Merajver travel out to the ALK Positive Summit in Nashville, TN, to host an unprecedented in-field research blood collection.

ALK Summit 2023

• July 23, 2023: Dr. Angel Qin presents at the ALK Summit at 9:15-10:00 AM: University of Michigan Initiative, Defining the molecular aspects of ALK-positive NSCLC to find new treatments.

Uniting Voices: Dr. Angel Qin and ALK Patient Jeff Sturm Explore U-M’s Groundbreaking Initiative.

ALK Summit 2022

• July 30, 2022: Dr. Sofia Merajver, Dr. Angel Qin, and Dr. Shirish Gadgeel present at ALK Positive Summit 2022.

Pioneering Personalized Treatments: U-M Highlights from the ALK Positive Summit 2022!